By Michele Maatouk
Date: Wednesday 05 Aug 2026
(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
| Currency | US Dollars |
| Share Price | $ 1,183.16 |
| Change Today | $ 3.00 |
| % Change | 0.25 % |
| 52 Week High | $1,235.56 |
| 52 Week Low | $695.33 |
| Volume | 1,805,562 |
| Shares Issued | 944.80m |
| Market Cap | $1,117,850m |
| RiskGrade | 179 |
| Time | Volume / Share Price |
| 16:03 | 240,757 @ $1,183.16 |
| 16:00 | 860 @ $1,185.16 |
| 15:59 | 75 @ $1,184.60 |
| 15:59 | 118 @ $1,185.05 |
| 15:59 | 40 @ $1,185.05 |
You are here: research